



9th Symposium: * FROM BENCH TO BEDSIDE Translational Research – Bridging Science to Application

June 27th, 2013, BioMedizinZentrumDortmund, Germany

Open Innovation: Game Changing approach to the Pharmaceutical R&D Process?

Dear Ladies and Gentlemen,

The so-called 'patent cliff' has been a much discussed and feared event in the pharmaceutical industry. Of the 133 blockbuster drugs that account for 34% of the market, 13 are coming out of patent in the US and European markets in 2013, and even more by 2015. Estimated \$250bn in sales will be wiped out by the middle of the decade. European pharmaceutical companies alone stand to lose somewhere in the region of \$10bn of US sales if no new products will fill the shrinking drug pipeline. In order to sustain Europe's position in the global health care business new approaches in the pharmaceutical R&D process are being discussed such as Crowd Sourcing and Open Innovation. By joining forces of academia, SMEs and (in)between the pharmaceutical companies in drug discovery projects it is expected to achieve faster and more effective ways to generate new and safe drug candidates.

One R&D focus in the life sciences activities at the TechnologieZentrum in Dortmund is on new concepts and technologies for effective drug discovery processes in close cooperation with the pharmaceutical industry and academic institutions. Several research groups and companies located in the BioMedizinZentrum have extensive small molecules expertise and are involved in various steps of the drug discovery value chain, such as syntheses services, novel chemistry research undertakings, medicinal chemistry research, hit to lead identification, lead validation and lead development.

The Economic Development Agency Dortmund together with BioMedizinZentrum-Dortmund and Taros Chemicals GmbH would like to invite you to our one-day symposium. This symposium will offer a comprehensive view on today's pharma R&D challenges and specific opportunities "Open Innovation" could provide to tackle these challenge. You will also get the chance to take a closer look behind the scenes

of the "European Lead Factory", a €196m budgeted PPP drug discovery platform and likely Europe's largest single Innovative Medicines Initiative (IMI) supported undertaking that IMI Executive Director Michel Goldmann has qualified as "a unique project of how a public-private partnership can transform the way in which the pharmaceutical sector identifies new medicines".

The symposium will also showcase established R&D projects and their approaches towards speeding up and improving integrative drug discovery in Europe.

International speakers from academia, industry and the European Commission will help addressing these challenging questions and are available for F2F discussions during the day.

We are looking forward to welcoming you in Dortmund.

Venue

BioMedizinZentrumDortmund, Otto-Hahn-Str. 15
44227 Dortmund, Germany

Contact

Economic Development Agency Dortmund
dortmund-project
Töllnerstraße 9-11, 44122 Dortmund, Germany

Frank Gutzmerow
frank.gutzmerow@stadtdo.de
+49(0)231 5024119

Asita Weissenberger
asita.weissenberger@stadtdo.de
+49(0)231 5029217

Registration

www.biotechnology-dortmund.com

Organisation:

Partner:



In cooperation:

BioIndustry



City of Dortmund
Economic Development
Agency





9th Symposium: * FROM BENCH TO BEDSIDE

Translational Research – Bridging Science to Application

June 27th, 2013, BioMedizinZentrumDortmund, Germany

Open Innovation: Game Changing approach to the Pharmaceutical R&D Process?

Program

09.45 **Registration**

10.15 **Welcome / Introduction**

10.30 **Drug Discovery & Development: Facts & Visions**

Prof. Dr. Axel Kleemann

Prof. Kleemann is former Executive Board member of ASTAMedica AG with responsibility for R&D, Production & Engineering & Drug Safety. Since 2000 until today he is consultant and member of Supervisory and Scientific Boards of several biotech, chemical and pharmaceutical companies and author of several books.

11.00 **European Lead Factory: Game Changing for innovative Medicines**

Dr. Ton Rijnders

Before joining Top Institute Pharma as Scientific Director, Ton Rijnders held several management positions at Organon from 1986-2011. He is Head of the Screening Consortium of the European Lead Factory.

11.30 **Open Innovation at Bayer Pharma**

Dr. Jörg Hüser

Currently Jörg Hüser holds the position of Vice President, Head of Lead Discovery at Bayer Pharma AG Wuppertal and EFPIA Coordinator of the European Lead Factory.

12.00 **Lunch Break**

13.30 **(Open) Innovation in Early Drug Discovery**

Dr. Peter Nussbaumer

Before joining the Lead Discovery Center GmbH (LDC) as Managing Director, Peter Nussbaumer held various positions in the area of medicinal chemistry with Sandoz and Novartis Institutes for Biomedical Research.

14.00 **Open innovation in the pharmaceutical industry: the role of public-private partnerships**

Dr. Hugh Lavery

Since 2011, Hugh Lavery is Scientific Manager at Innovative Medicine Initiative Joint Undertaking (IMI JU), Brussels. IMI is a public-private partnership between the Pharmaceutical Industry (EFPIA) and the European Communities (EC) with the goal to stimulate innovative research.

14.30 **Coffee Break**

15.00 **„Open Innovation and Crowd Sourcing“ on the Example of the European Lead Factory**

Dr. Dimitrios Tzalis

Dimitrios Tzalis has founded Taros Chemicals in 1999. Until today, he serves as the company's CEO. Dimitrios Tzalis is Head of the Chemistry Consortium of the European Lead Factory.

15.30 **Wrap-up / Get-together**

Partner:



In cooperation:

BioIndustry



Organisation:



City of Dortmund
Economic Development
Agency

